Pramlintide acetate is an injectable human amylin analog that has been launched for the treatment of both type 1 and type 2 diabetes, in conjunction with insulin. While it is also a 37-amino acid peptide, it differs from its parent predecessor by the substitution of Ala-25, Ser-28, and Ser-29 with prolines. Not only do these modifications improve the solubility of the peptide, they also eliminate the aggregation observed with amylin, resulting in a stable synthetic analog with retention of biological activity that is suitable for pharmaceutical use.
Related Prodcuts:
Icatibant; Lanreotide; Nesiritide; Leuprolide Acetate; Liraglutide; Lypressin; Atosiban; Oxytocin; Pasireotide; Bivalirudin; Calcitonin Salmon; Alarelin Acetate; Sincalide; Somatostatin Acetate; Glucagon HCl